search
Back to results

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)

Primary Purpose

Multiple Myeloma

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Nivolumab
Elotuzumab
Pomalidomide
Dexamethasone
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Myeloma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Refractory or relapsed and refractory multiple myeloma
  • Measurable disease
  • Have received ≥ 2 lines of prior therapy which must have included an immune modulatory drug (IMiD) and a proteasome inhibitor alone or in combination

Exclusion Criteria:

  • Solitary bone or extramedullary plasmacytoma disease only
  • Active plasma cell leukemia

Other protocol defined inclusion/exclusion criteria apply

Sites / Locations

  • Local Institution - 0020
  • Local Institution - 0160
  • Local Institution - 0163
  • Local Institution - 0118
  • Local Institution - 0093
  • Local Institution - 0016
  • Local Institution - 0164
  • UC San Diego Moores Cancer Ctr
  • Local Institution - 0138
  • Local Institution - 0155
  • Local Institution - 0117
  • Local Institution - 0092
  • Coastal Integrative Cancer Care
  • Local Institution - 0113
  • Colorado Blood Cancer Institute
  • Poudre Valley Health Care
  • Local Institution - 0116
  • Yale University School Of Medicine
  • Local Institution - 0147
  • Local Institution - 0011
  • Florida Cancer Specialists S.
  • Local Institution - 0114
  • Cancer Specialists of North FL
  • Local Institution - 0082
  • Local Institution - 0126
  • Local Institution - 0130
  • Local Institution - 0125
  • Local Institution - 0119
  • Local Institution - 0009
  • Local Institution - 0024
  • Augusta University
  • Local Institution - 0035
  • Local Institution - 0111
  • Indiana University Cancer Ctr
  • Local Institution - 0018
  • Local Institution - 0006
  • Local Institution - 0123
  • Local Institution - 0150
  • Local Institution - 0137
  • St. Louis Cancer Care, Llp
  • Local Institution - 0128
  • Washington University
  • Local Institution - 0049
  • Local Institution - 0079
  • Local Institution - 0076
  • Local Institution - 0002
  • Local Institution - 0095
  • Local Institution - 0142
  • Local Institution - 0010
  • Broome Oncology LLC
  • Mount Sinai Medical Center
  • Local Institution - 0017
  • Local Institution - 0001
  • Local Institution - 0096
  • Local Institution - 0012
  • University Of Oklahoma
  • Local Institution - 0145
  • Local Institution - 0136
  • Local Institution - 0021
  • Local Institution - 0036
  • Local Institution - 0152
  • Local Institution - 0069
  • Tennessee Oncology, PLLC - SCRI - PPDS
  • Baylor Research Institute
  • Local Institution - 0044
  • Local Institution - 0037
  • Local Institution - 0046
  • Local Institution - 0022
  • Local Institution - 0153
  • Emily Couric Clinical Cancer Center
  • Virginia Cancer Institute
  • Local Institution - 0144
  • Local Institution - 0029
  • Universitaetsklinik Salzburg
  • Local Institution - 0026
  • Klinikum Wels-Grieskirchen Gmbh
  • Wilhelminenspital
  • Local Institution
  • Local Institution
  • Local Institution - 0074
  • Local Institution - 0039
  • MUHC - Glen Site
  • Local Institution - 0154
  • Local Institution - 0157
  • Local Institution
  • Interni hematologicka a onkologicka klinika
  • Klinika hematoonkologie
  • I. interni klinika - klinika hematologie 1. LF UK a VFN v Praze
  • Local Institution
  • Local Institution
  • Local Institution - 0050
  • Universitaetsklinikum Carl Gustav Carus
  • Uniklinikum Duesseldorf
  • Local Institution - 0135
  • Klinikum Der Johannes Gutenberg Universitaet Mainz
  • Local Institution - 0054
  • Alexandra General Hospital Of Athens
  • Local Institution - 0087
  • Local Institution
  • Local Institution
  • Local Institution
  • Local Institution
  • Local Institution - 0042
  • Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona
  • Local Institution - 0089
  • A. O. U. Di Bologna, Policlinico S. Orsola Malpighi
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
  • Azienda Ospedaliera Santa Maria Terni
  • Local Institution
  • Local Institution - 0075
  • Local Institution - 0132
  • Local Institution
  • Local Institution - 0071
  • Local Institution - 0101
  • Local Institution - 0098
  • Local Institution - 0100
  • Local Institution - 0097
  • Local Institution - 0099
  • Local Institution - 0064
  • Hopitaux Universitaires de Geneve
  • Local Institution - 0186

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Experimental

Arm Label

Investigational Arm

Control Arm

Exploratory Arm

Arm Description

Nivolumab, Pomalidomide and Dexamethasone Enrollment is closed for this arm

Pomalidomide and Dexamethasone Enrollment is closed for this arm

Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone Enrollment is closed for this arm

Outcomes

Primary Outcome Measures

Progression Free Survival (PFS)
Randomization to first documented tumor progression or death due to any cause, whichever occurred first. Participants who die without reported prior progression are considered to have progressed on date of their death. Participants who did not progress or die will be censored at their last efficacy assessment. Participants who did not have on study efficacy assessments and alive will be censored on randomization date. Participants who started subsequent anti-cancer therapy without prior reported progression will be censored at last efficacy assessment prior to subsequent anti-cancer therapy. Progression is 1) increase of 25% from lowest confirmed response value in specific Serum M-protein and Urine M-protein criteria and increase of FLC for patients with no measurable M protein in blood or urine at baseline and/or 2) appearance of a new lesion(s), >/= 50% increase from nadir in SPD of > 1 lesion, or >/= 50% increase in the longest diameter of a previous lesion > 1 cm in short axis.

Secondary Outcome Measures

Overall Survival (OS)
The time between the date of randomization and the date of death due to any cause. OS will be censored on the last date a participant was known to be alive.
Objective Response Rate (ORR)
The percentage of randomized participants who achieved a best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) using International Myeloma Working Group (IMWG) criteria. sCR= Complete response as defined below plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry. CR = Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow aspirates. VGPR = Serum and urine M-protein detectable by immunofixation but not on electrophoresis or >/= 90% reduction in serum M-protein plus urine M-protein level < 100 mg per 24 h. PR = >/= 50% reduction of serum M-protein plus reduction in 24 h urinary M-protein by >/= 90% or to < 200 mg per 24 h.
Time to Objective Response (TTR)
The time from the date of randomization to the date of the first stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR= Complete response as defined below plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry. CR = Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow aspirates. VGPR = Serum and urine M-protein detectable by immunofixation but not on electrophoresis or >/= 90% reduction in serum M-protein plus urine M-protein level < 100 mg per 24 h. PR = >/= 50% reduction of serum M-protein plus reduction in 24 h urinary M-protein by >/= 90% or to < 200 mg per 24 h.
Duration of Objective Response (DOR)
The time between the date of first response to the date of the first objectively documented tumor progression as assessed by the investigator according to International Myeloma Working Group (IMWG) criteria or death due to any cause prior to subsequent anti-cancer therapy. Participants who neither progress nor die will be censored on the date of their last tumor assessment prior to subsequent anti-cancer therapy. Progression is 1) increase of 25% from lowest confirmed response value in specific Serum M-protein and Urine M-protein criteria and increase of FLC for patients with no measurable M protein in blood or urine at baseline and/or 2) appearance of a new lesion(s), >/= 50% increase from nadir in SPD of > 1 lesion, or >/= 50% increase in the longest diameter of a previous lesion > 1 cm in short axis.

Full Information

First Posted
March 23, 2016
Last Updated
February 28, 2023
Sponsor
Bristol-Myers Squibb
Collaborators
AbbVie
search

1. Study Identification

Unique Protocol Identification Number
NCT02726581
Brief Title
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
Acronym
CheckMate 602
Official Title
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
August 10, 2016 (Actual)
Primary Completion Date
March 9, 2022 (Actual)
Study Completion Date
March 9, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb
Collaborators
AbbVie

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone. Enrollment is closed for all groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Myeloma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
170 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Investigational Arm
Arm Type
Experimental
Arm Description
Nivolumab, Pomalidomide and Dexamethasone Enrollment is closed for this arm
Arm Title
Control Arm
Arm Type
Active Comparator
Arm Description
Pomalidomide and Dexamethasone Enrollment is closed for this arm
Arm Title
Exploratory Arm
Arm Type
Experimental
Arm Description
Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone Enrollment is closed for this arm
Intervention Type
Biological
Intervention Name(s)
Nivolumab
Other Intervention Name(s)
BMS-936558
Intervention Description
Specified dose on specified days, IV (intravenous)
Intervention Type
Biological
Intervention Name(s)
Elotuzumab
Other Intervention Name(s)
BMS-901608
Intervention Description
Specified dose on specified days, IV
Intervention Type
Drug
Intervention Name(s)
Pomalidomide
Intervention Description
Specified dose on specified days, PO (by mouth)
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Description
Specified dose on specified days, PO
Primary Outcome Measure Information:
Title
Progression Free Survival (PFS)
Description
Randomization to first documented tumor progression or death due to any cause, whichever occurred first. Participants who die without reported prior progression are considered to have progressed on date of their death. Participants who did not progress or die will be censored at their last efficacy assessment. Participants who did not have on study efficacy assessments and alive will be censored on randomization date. Participants who started subsequent anti-cancer therapy without prior reported progression will be censored at last efficacy assessment prior to subsequent anti-cancer therapy. Progression is 1) increase of 25% from lowest confirmed response value in specific Serum M-protein and Urine M-protein criteria and increase of FLC for patients with no measurable M protein in blood or urine at baseline and/or 2) appearance of a new lesion(s), >/= 50% increase from nadir in SPD of > 1 lesion, or >/= 50% increase in the longest diameter of a previous lesion > 1 cm in short axis.
Time Frame
From randomization to the date of the first documented tumor progression or death due to any cause, whichever occurred first (Up to approximately 64 month)
Secondary Outcome Measure Information:
Title
Overall Survival (OS)
Description
The time between the date of randomization and the date of death due to any cause. OS will be censored on the last date a participant was known to be alive.
Time Frame
From randomization to the date of death due to any cause (up to approximately 64 months)
Title
Objective Response Rate (ORR)
Description
The percentage of randomized participants who achieved a best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) using International Myeloma Working Group (IMWG) criteria. sCR= Complete response as defined below plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry. CR = Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow aspirates. VGPR = Serum and urine M-protein detectable by immunofixation but not on electrophoresis or >/= 90% reduction in serum M-protein plus urine M-protein level < 100 mg per 24 h. PR = >/= 50% reduction of serum M-protein plus reduction in 24 h urinary M-protein by >/= 90% or to < 200 mg per 24 h.
Time Frame
From randomization up to approximately 64 months
Title
Time to Objective Response (TTR)
Description
The time from the date of randomization to the date of the first stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR= Complete response as defined below plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry. CR = Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow aspirates. VGPR = Serum and urine M-protein detectable by immunofixation but not on electrophoresis or >/= 90% reduction in serum M-protein plus urine M-protein level < 100 mg per 24 h. PR = >/= 50% reduction of serum M-protein plus reduction in 24 h urinary M-protein by >/= 90% or to < 200 mg per 24 h.
Time Frame
From the date of randomization to the date of the first sCR, CR, VGPR, or PR (up to approximately 64 months)
Title
Duration of Objective Response (DOR)
Description
The time between the date of first response to the date of the first objectively documented tumor progression as assessed by the investigator according to International Myeloma Working Group (IMWG) criteria or death due to any cause prior to subsequent anti-cancer therapy. Participants who neither progress nor die will be censored on the date of their last tumor assessment prior to subsequent anti-cancer therapy. Progression is 1) increase of 25% from lowest confirmed response value in specific Serum M-protein and Urine M-protein criteria and increase of FLC for patients with no measurable M protein in blood or urine at baseline and/or 2) appearance of a new lesion(s), >/= 50% increase from nadir in SPD of > 1 lesion, or >/= 50% increase in the longest diameter of a previous lesion > 1 cm in short axis.
Time Frame
From randomization to the date of the first objectively documented tumor progression or death due to any cause prior to subsequent anti-cancer therapy (up to approximately 64 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Refractory or relapsed and refractory multiple myeloma Measurable disease Have received ≥ 2 lines of prior therapy which must have included an immune modulatory drug (IMiD) and a proteasome inhibitor alone or in combination Exclusion Criteria: Solitary bone or extramedullary plasmacytoma disease only Active plasma cell leukemia Other protocol defined inclusion/exclusion criteria apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution - 0020
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294-3300
Country
United States
Facility Name
Local Institution - 0160
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Facility Name
Local Institution - 0163
City
Fayetteville
State/Province
Arkansas
ZIP/Postal Code
72703
Country
United States
Facility Name
Local Institution - 0118
City
Bakersfield
State/Province
California
ZIP/Postal Code
93309
Country
United States
Facility Name
Local Institution - 0093
City
Corona
State/Province
California
ZIP/Postal Code
92879
Country
United States
Facility Name
Local Institution - 0016
City
Fountain Valley
State/Province
California
ZIP/Postal Code
92708
Country
United States
Facility Name
Local Institution - 0164
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
UC San Diego Moores Cancer Ctr
City
La Jolla
State/Province
California
ZIP/Postal Code
92093-0698
Country
United States
Facility Name
Local Institution - 0138
City
Los Angeles
State/Province
California
ZIP/Postal Code
90017
Country
United States
Facility Name
Local Institution - 0155
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Local Institution - 0117
City
Redondo Beach
State/Province
California
ZIP/Postal Code
90277
Country
United States
Facility Name
Local Institution - 0092
City
Riverside
State/Province
California
ZIP/Postal Code
92501
Country
United States
Facility Name
Coastal Integrative Cancer Care
City
San Luis Obispo
State/Province
California
ZIP/Postal Code
93401
Country
United States
Facility Name
Local Institution - 0113
City
Santa Maria
State/Province
California
ZIP/Postal Code
93454
Country
United States
Facility Name
Colorado Blood Cancer Institute
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
Poudre Valley Health Care
City
Fort Collins
State/Province
Colorado
ZIP/Postal Code
80528
Country
United States
Facility Name
Local Institution - 0116
City
Grand Junction
State/Province
Colorado
ZIP/Postal Code
81501
Country
United States
Facility Name
Yale University School Of Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
Local Institution - 0147
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Facility Name
Local Institution - 0011
City
Boynton Beach
State/Province
Florida
ZIP/Postal Code
33426
Country
United States
Facility Name
Florida Cancer Specialists S.
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33916
Country
United States
Facility Name
Local Institution - 0114
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Facility Name
Cancer Specialists of North FL
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256
Country
United States
Facility Name
Local Institution - 0082
City
Pensacola
State/Province
Florida
ZIP/Postal Code
32504
Country
United States
Facility Name
Local Institution - 0126
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33705
Country
United States
Facility Name
Local Institution - 0130
City
Tallahassee
State/Province
Florida
ZIP/Postal Code
32308
Country
United States
Facility Name
Local Institution - 0125
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Facility Name
Local Institution - 0119
City
Athens
State/Province
Georgia
ZIP/Postal Code
30607
Country
United States
Facility Name
Local Institution - 0009
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30318
Country
United States
Facility Name
Local Institution - 0024
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Augusta University
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912
Country
United States
Facility Name
Local Institution - 0035
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Local Institution - 0111
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46845
Country
United States
Facility Name
Indiana University Cancer Ctr
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
Local Institution - 0018
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20817
Country
United States
Facility Name
Local Institution - 0006
City
Baltimore
State/Province
Massachusetts
ZIP/Postal Code
21229
Country
United States
Facility Name
Local Institution - 0123
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01655
Country
United States
Facility Name
Local Institution - 0150
City
Ypsilanti
State/Province
Michigan
ZIP/Postal Code
48197
Country
United States
Facility Name
Local Institution - 0137
City
Hattiesburg
State/Province
Mississippi
ZIP/Postal Code
39401
Country
United States
Facility Name
St. Louis Cancer Care, Llp
City
Bridgeton
State/Province
Missouri
ZIP/Postal Code
63044
Country
United States
Facility Name
Local Institution - 0128
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64132
Country
United States
Facility Name
Washington University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Local Institution - 0049
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65806
Country
United States
Facility Name
Local Institution - 0079
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68510
Country
United States
Facility Name
Local Institution - 0076
City
Flemington
State/Province
New Jersey
ZIP/Postal Code
08822
Country
United States
Facility Name
Local Institution - 0002
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Facility Name
Local Institution - 0095
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08903
Country
United States
Facility Name
Local Institution - 0142
City
Paramus
State/Province
New Jersey
ZIP/Postal Code
07652
Country
United States
Facility Name
Local Institution - 0010
City
Buffalo
State/Province
New York
ZIP/Postal Code
14263
Country
United States
Facility Name
Broome Oncology LLC
City
Johnson City
State/Province
New York
ZIP/Postal Code
13790
Country
United States
Facility Name
Mount Sinai Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Local Institution - 0017
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
Local Institution - 0001
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Local Institution - 0096
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
Local Institution - 0012
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43219
Country
United States
Facility Name
University Of Oklahoma
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Facility Name
Local Institution - 0145
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Facility Name
Local Institution - 0136
City
Lancaster
State/Province
Pennsylvania
ZIP/Postal Code
17604
Country
United States
Facility Name
Local Institution - 0021
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Local Institution - 0036
City
Sayre
State/Province
Pennsylvania
ZIP/Postal Code
18840
Country
United States
Facility Name
Local Institution - 0152
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29605
Country
United States
Facility Name
Local Institution - 0069
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Facility Name
Tennessee Oncology, PLLC - SCRI - PPDS
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Baylor Research Institute
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Name
Local Institution - 0044
City
Houston
State/Province
Texas
ZIP/Postal Code
77090
Country
United States
Facility Name
Local Institution - 0037
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Local Institution - 0046
City
Temple
State/Province
Texas
ZIP/Postal Code
76508-0001
Country
United States
Facility Name
Local Institution - 0022
City
Ogden
State/Province
Utah
ZIP/Postal Code
84403
Country
United States
Facility Name
Local Institution - 0153
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84106
Country
United States
Facility Name
Emily Couric Clinical Cancer Center
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States
Facility Name
Virginia Cancer Institute
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23230
Country
United States
Facility Name
Local Institution - 0144
City
Seattle
State/Province
Washington
ZIP/Postal Code
98108
Country
United States
Facility Name
Local Institution - 0029
City
Linz
ZIP/Postal Code
4020
Country
Austria
Facility Name
Universitaetsklinik Salzburg
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Facility Name
Local Institution - 0026
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Klinikum Wels-Grieskirchen Gmbh
City
Wels
ZIP/Postal Code
4600
Country
Austria
Facility Name
Wilhelminenspital
City
Wien
ZIP/Postal Code
1160
Country
Austria
Facility Name
Local Institution
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
Facility Name
Local Institution
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 1M9
Country
Canada
Facility Name
Local Institution - 0074
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Facility Name
Local Institution - 0039
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2X 3E4
Country
Canada
Facility Name
MUHC - Glen Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Facility Name
Local Institution - 0154
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4J 1C5
Country
Canada
Facility Name
Local Institution - 0157
City
Rimouski
State/Province
Quebec
ZIP/Postal Code
G5L 5T1
Country
Canada
Facility Name
Local Institution
City
Quebec
ZIP/Postal Code
G1R 2J6
Country
Canada
Facility Name
Interni hematologicka a onkologicka klinika
City
Brno
ZIP/Postal Code
625 00
Country
Czechia
Facility Name
Klinika hematoonkologie
City
Ostrava-Poruba
ZIP/Postal Code
708 52
Country
Czechia
Facility Name
I. interni klinika - klinika hematologie 1. LF UK a VFN v Praze
City
Praha 2
ZIP/Postal Code
128 08
Country
Czechia
Facility Name
Local Institution
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
Facility Name
Local Institution
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Facility Name
Local Institution - 0050
City
Berlin
ZIP/Postal Code
12200
Country
Germany
Facility Name
Universitaetsklinikum Carl Gustav Carus
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Uniklinikum Duesseldorf
City
Duesseldorf
ZIP/Postal Code
40225
Country
Germany
Facility Name
Local Institution - 0135
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Facility Name
Klinikum Der Johannes Gutenberg Universitaet Mainz
City
Mainz
ZIP/Postal Code
55101
Country
Germany
Facility Name
Local Institution - 0054
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Facility Name
Alexandra General Hospital Of Athens
City
Athens
ZIP/Postal Code
11528
Country
Greece
Facility Name
Local Institution - 0087
City
Beer Sheva
ZIP/Postal Code
84101
Country
Israel
Facility Name
Local Institution
City
Jerusalem
ZIP/Postal Code
9112001
Country
Israel
Facility Name
Local Institution
City
Petah Tikva
ZIP/Postal Code
4941492
Country
Israel
Facility Name
Local Institution
City
Ramat-gan
ZIP/Postal Code
52621
Country
Israel
Facility Name
Local Institution
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel
Facility Name
Local Institution - 0042
City
Torino
State/Province
Piemonte
ZIP/Postal Code
10126
Country
Italy
Facility Name
Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona
City
Ancona
ZIP/Postal Code
60126
Country
Italy
Facility Name
Local Institution - 0089
City
Bergamo
ZIP/Postal Code
24127
Country
Italy
Facility Name
A. O. U. Di Bologna, Policlinico S. Orsola Malpighi
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Facility Name
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
City
Meldola (FC)
ZIP/Postal Code
47014
Country
Italy
Facility Name
Azienda Ospedaliera Santa Maria Terni
City
Terni
ZIP/Postal Code
05100
Country
Italy
Facility Name
Local Institution
City
Oslo
ZIP/Postal Code
0372
Country
Norway
Facility Name
Local Institution - 0075
City
Stavanger
ZIP/Postal Code
4011
Country
Norway
Facility Name
Local Institution - 0132
City
Lisbon
State/Province
Lisboa
ZIP/Postal Code
1400-038
Country
Portugal
Facility Name
Local Institution
City
Porto
ZIP/Postal Code
4200-072
Country
Portugal
Facility Name
Local Institution - 0071
City
San Juan
ZIP/Postal Code
00918
Country
Puerto Rico
Facility Name
Local Institution - 0101
City
Pozuelo De Alarcon
State/Province
Madrid
ZIP/Postal Code
28223
Country
Spain
Facility Name
Local Institution - 0098
City
Badalona-Barcelona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Local Institution - 0100
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Local Institution - 0097
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Facility Name
Local Institution - 0099
City
Salamanca
ZIP/Postal Code
37007
Country
Spain
Facility Name
Local Institution - 0064
City
Huddinge
ZIP/Postal Code
14186
Country
Sweden
Facility Name
Hopitaux Universitaires de Geneve
City
Geneve
ZIP/Postal Code
1211
Country
Switzerland
Facility Name
Local Institution - 0186
City
Istanbul
ZIP/Postal Code
34899
Country
Turkey

12. IPD Sharing Statement

Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
https://www.bmsstudyconnect.com/s/US/English/USenHome
Description
BMS Clinical Trial Patient Recruiting
URL
https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm
Description
FDA Safety Alerts and Recalls

Learn more about this trial

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

We'll reach out to this number within 24 hrs